STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Gilmore O'Neill, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.

Interested parties can access a live webcast of the presentation through the "Investors" section of the Editas Medicine website. The presentation recording will remain available on the company's website for approximately 30 days after the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.

A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.

About Editas Medicine
As a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.


FAQ

When is Editas Medicine (EDIT) presenting at the 2025 J.P. Morgan Healthcare Conference?

Editas Medicine will present on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.

How can investors watch Editas Medicine's (EDIT) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on the 'Investors' section of the Editas Medicine website at www.editasmedicine.com.

How long will Editas Medicine's (EDIT) 2025 J.P. Morgan presentation be available for replay?

An archived replay of the presentation will be available on the Editas Medicine website for approximately 30 days following the presentation.

Who will represent Editas Medicine (EDIT) at the 2025 J.P. Morgan Healthcare Conference?

Gilmore O'Neill, President and CEO of Editas Medicine, will represent the company at the conference.
Editas Medicine Inc

NASDAQ:EDIT

EDIT Rankings

EDIT Latest News

EDIT Latest SEC Filings

EDIT Stock Data

234.28M
97.34M
0.3%
49.2%
8.69%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE